BioCentury
ARTICLE | Regulation

Herculean task for DMD

How Duchenne UK’s HERCULES consortium hopes to improve access to DMD therapies

February 24, 2018 12:54 AM UTC

Driven by the delayed reimbursement decision for Europe’s only approved DMD therapy, the patient advocacy group Duchenne UK has brought together seven companies in the space to create a set of shared tools that should expedite HTA evaluations for all of their therapies.

Project HERCULES was launched in January with Pfizer Inc., PTC Therapeutics Inc., Roche, Sarepta Therapeutics Inc., Solid Biosciences Inc., Summit Therapeutics plc and Wave Life Sciences Ltd. Steering Committee members include CureDuchenne and Parent Project Muscular Dystrophy (PPMD)...